1228014-22-9 Usage
Uses
Used in Pharmaceutical Industry:
5-Bromo-6-methylpicolinamide is used as a building block for the synthesis of pharmaceutical compounds due to its versatile reactivity and functional groups. It contributes to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Bromo-6-methylpicolinamide is utilized as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its unique chemical structure allows for the creation of effective compounds to protect crops and control pests.
Used in Antitumor Research:
5-Bromo-6-methylpicolinamide is studied as a potential anti-tumor agent. Its chemical properties and reactivity make it a promising candidate for the development of new cancer treatments, targeting specific tumor cells and inhibiting their growth.
Used in Antimicrobial Applications:
BMMP has been investigated for its antimicrobial properties, making it a potential candidate for use in the development of new antimicrobial agents. Its ability to target and inhibit the growth of various microorganisms can contribute to the creation of effective treatments for infectious diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 1228014-22-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,0,1 and 4 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1228014-22:
(9*1)+(8*2)+(7*2)+(6*8)+(5*0)+(4*1)+(3*4)+(2*2)+(1*2)=109
109 % 10 = 9
So 1228014-22-9 is a valid CAS Registry Number.
1228014-22-9Relevant academic research and scientific papers
Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223
Mortensen, Deborah S.,Perrin-Ninkovic, Sophie M.,Shevlin, Graziella,Zhao, Jingjing,Packard, Garrick,Bahmanyar, Sogole,Correa, Matthew,Elsner, Jan,Harris, Roy,Lee, Branden G. S.,Papa, Patrick,Parnes, Jason S.,Riggs, Jennifer R.,Sapienza, John,Tehrani, Lida,Whitefield, Brandon,Apuy, Julius,Bisonette, René R.,Gamez, James C.,Hickman, Matt,Khambatta, Godrej,Leisten, Jim,Peng, Sophie X.,Richardson, Samantha J.,Cathers, Brian E.,Canan, Stacie S.,Moghaddam, Mehran F.,Raymon, Heather K.,Worland, Peter,Narla, Rama Krishna,Fultz, Kimberly E.,Sankar, Sabita
, p. 5323 - 5333 (2015/08/03)
We report here the synthesis and structure-activity relationship (SAR) of a novel series of mammalian target of rapamycin (mTOR) kinase inhibitors. A series of 4,6- or 1,7-disubstituted-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-ones were optimized for in v
MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY
-
Page/Page column 113, (2010/06/17)
Provided herein are Heteroaryl Compounds having the following structure: R2 N (I) or (II) wherein R1 -R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
